<DOC>
	<DOCNO>NCT01330186</DOCNO>
	<brief_summary>The purpose study evaluate predictive value 18F-fluoromisonidazol-PET ( FMISO-PET ) , 2-18F-fluoro-2-deoxy-d-glukose-PET-CT ( FDG-PET-CT ) , Diffusion-Weighted Magnetic Resonance Imaging ( DWI-MRI ) Dynamic Contrast-Enhanced Magnetic Resonance Imaging ( DCE-MRI ) patient anal cancer receive radiation therapy +/- chemotherapy ( Cisplatin 5-FU ) .</brief_summary>
	<brief_title>Predictive Value FMISO-PET , FDG-PET-CT , DWI-MRI DCE-MRI Scans Patients With Anal Cancer Receiving Radiotherapy +/- Chemotherapy</brief_title>
	<detailed_description>The study involve tree MRI session , two FDG-PET-CT session one FMISO-PET session . The FMISO-PET session presently carry delivery problem . The production 18F-fluoromisonidazol The Department Clinical Physiology Nuclear Medicine , Copenhagen University Hospital Herlev , Denmark jet approve Danish Medicines Agency .</detailed_description>
	<mesh_term>Anus Neoplasms</mesh_term>
	<criteria>Histological confirmation invasive primary squamous cell carcinoma anal canal perianal region . TNM stage T14 , N03 , M01 Treatment curative intent Age &gt; 18 year Able provide inform consent Contraindication MRI image Cardiac pacemaker Major obesity Serious claustrophobia Other malignant disease ( except nonmelanoma skin cancer ) period 5 year prior image study Poorly regulate diabetes mellitus despite insulin Pregnancy Breast feed Known allergy iv contrast agent Major psychiatric illness would prevent participation image study Infectious wound legs Unacceptable kidney function Major language difficulty would prevent participation imaging study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>